NOISEReport
Coverage history

Assembled by NOISE.

Report / Business

Published by NOISE

FDA approves pancreatic cancer pill that nearly doubles average survival

From Evening NOISE.

The FDA approved daraxonrasib, also known as Rasonque, a daily tablet developed by Revolution Medicines for pancreatic cancer. The Washington Post reports that clinical trials found the drug nearly doubled average survival compared with chemotherapy, potentially changing treatment for a cancer with a historically poor prognosis.

Saved versions

These dates record changes to NOISE’s copy. They are not event dates.

  1. Retained copyCurrentIn saved edition